On October 2, 2018 Jnana Therapeutics reported that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry (Press release, Jnana Therapeutics, OCT 2, 2018, View Source [SID1234529773]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jnana Therapeutics was launched in 2017 to build the first drug discovery platform targeting the solute carrier (SLC) family of metabolite transporters, which are the gates used by the cell to control metabolite movement. The company is taking a comprehensive approach to understanding SLCs and their underlying biology in order to unlock a new wave of druggable targets. From there, they are discovering and developing medicines to modulate critical disease pathways to improve outcomes for patients with severe diseases.

"We are pleased to be recognized as a Fierce 15 company, an award which reflects the innovative nature of our drug discovery platform and its potential to unlock SLC transporters as a novel therapeutic target class," said Joanne Kotz, Ph.D., Cofounder and President at Jnana. "Our purpose at Jnana is to push the frontiers of scientific knowledge by pioneering the comprehensive understanding and targeting of the SLC transporter family, which has never been systematically addressed in drug development, and create a new class of medicines that make a positive impact on patients and their families."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s 16th annual Fierce 15 selection.

An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

On October 2, 2018 Kronos Bio, Inc. (Kronos), a Two River portfolio company, reported that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry for its pursuit of novel therapies against some of the most important and intractable targets in cancer research (Press release, Kronos Bio, OCT 2, 2018, View Source [SID1234529766]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"It is an honor to have Kronos named by FierceBiotech as one of their Fierce 15 biotechnology companies for 2018," said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. "Fierce adeptly describes our pursuit of targets many have viewed as ‘undruggable.’ We believe our small molecule microarray (SMM) technology will enable us to engage recalcitrant targets and develop innovative therapies for cancer and other life altering diseases."

The foundation of Kronos was built on over a decade of research into high-throughput screening strategies for chemical modulators of transcription factors and other recalcitrant targets in oncology. By combining small molecule microarrays with extensive know-how in biological assay development, Kronos’ technology platform enables high-throughput screens of chemical libraries against target proteins in a more physiologically relevant context. As a result, a single screening assay can identify compounds that bind or interfere with target protein activity directly, disrupt protein-protein or protein-DNA interactions, or indirectly modulate target protein activity by binding to co-factors or
other protein complex members. This approach is ideally suited for rapid discovery of unique ligands that can be utilized in the generation of novel modulators or degraders of historically challenging targets such as transcription factors.

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s 16th annual Fierce 15 selection. An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position

On October 2, 2018 Gossamer Bio, Inc. ("Gossamer Bio") reported that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry (Press release, Gossamer Bio, OCT 2, 2018, View Source [SID1234529746]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored to be selected as a Fierce 15 company for 2018," said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer Bio. "We have an exciting portfolio of innovative clinical and research stage programs across multiple indications that leverage our deep mechanistic understanding of immunobiology. With a focus on immunology, inflammation and immuno-oncology, our world-class team is committed to applying our collective expertise in discovery and development to bring forth important new medicines to patients who are suffering."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s 16th annual Fierce 15 selection.

An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

On October 2, 2018 Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, reported that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotech companies in the industry (Press release, Compass Therapeutics, OCT 2, 2018, View Source [SID1234529744]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Compass, which completed its $132 million Series A financing this year, is forging a new approach to identifying antibody drug candidates that engage all targets in the biologically complex human immune synapse. The company’s antibody discovery platform enables the rapid identification of therapeutic candidates that engage with a broad range of epitopes and its StitchMabs bispecific screening platform enables the empirical, high-throughput identification of novel synergistic combinations and bispecifics. To date, the company’s integrated R&D approach has generated therapeutic candidates for more than 30 targets in cancer, inflammation and autoimmune disease. More than 15 of them are now advancing through preclinical development.

"We’re honored that the editors of FierceBiotech have recognized Compass for our pioneering approach to antibody-based therapeutics," said Thomas Schuetz, M.D., Ph.D., the company’s co-founder and chief executive officer. "We believe our empirical, unbiased approach to drug discovery will lead to therapeutics with new mechanisms to modulate the human immune system."

The Fierce 15 celebrates the spirit of being "fierce"— championing innovation and creativity, even in the face of intense competition. Selection to the list is based on factors including the strength of a company’s technology, partnerships and venture backers and its competitive market position.

On October 2, 2018 SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, reported that data from the Phase 2b trial of nelipepimut-S (NeuVax) in combination with trastuzumab (Herceptin) for the treatment of women with triple-negative breast cancer (TNBC) will be presented in a poster presentation at the 2018 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, taking place November 9-11, 2018 in Washington, D.C (Press release, Sellas Life Sciences, OCT 2, 2018, View Source;Herceptin-at-the-2018-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting/default.aspx [SID1234529724]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentation are as follows:

Title: Correlation between response and HLA type in a randomized phase IIb trial of NeuVax + trastuzumab in HER2 low-expressing breast cancer patients to prevent recurrence
Poster Hall Location: Hall E
Poster Hall Hours: Friday, November 9 from 8:00 a.m. – 8:00 p.m. ET;
Saturday, November 10 from 8:00 a.m. – 8:30 p.m. ET
Abstract ID: 11073
SELLAS previously announced that the full dataset from the Phase 2b trial of nelipepimut-S (NeuVax) in combination with trastuzumab (Herceptin) will be presented in an oral presentation at the 2018 Annual Meeting of the European Society for Medical Oncology October 19-23 in Munich, Germany.